| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.03 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.9 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.028 | 0.9 |